Lucira Health (LHDXQ) and The Competition Financial Contrast

Defense World ·  Apr 16, 2023 13:32

Lucira Health (NASDAQ:LHDXQ – Get Rating) is one of 42 publicly-traded companies in the "Diagnostic substances" industry, but how does it compare to its rivals? We will compare Lucira Health to related businesses based on the strength of its valuation, institutional ownership, profitability, risk, dividends, analyst recommendations and earnings.

Valuation & Earnings

This table compares Lucira Health and its rivals revenue, earnings per share (EPS) and valuation.

Get Lucira Health alerts:
Gross Revenue Net Income Price/Earnings Ratio
Lucira Health $93.06 million -$64.83 million -0.05
Lucira Health Competitors $472.03 million $9.58 million -52.38

Lucira Health's rivals have higher revenue and earnings than Lucira Health. Lucira Health is trading at a higher price-to-earnings ratio than its rivals, indicating that it is currently more expensive than other companies in its industry.

Institutional and Insider Ownership

57.0% of Lucira Health shares are owned by institutional investors. Comparatively, 45.4% of shares of all "Diagnostic substances" companies are owned by institutional investors. 30.4% of Lucira Health shares are owned by company insiders. Comparatively, 14.1% of shares of all "Diagnostic substances" companies are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Volatility & Risk

Lucira Health has a beta of 3.36, indicating that its share price is 236% more volatile than the S&P 500. Comparatively, Lucira Health's rivals have a beta of 1.38, indicating that their average share price is 38% more volatile than the S&P 500.


This table compares Lucira Health and its rivals' net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Lucira Health -67.54% -13.55% -8.47%
Lucira Health Competitors -1,437.85% -124.65% -30.99%

Analyst Ratings

This is a summary of recent ratings and target prices for Lucira Health and its rivals, as provided by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Lucira Health 0 0 0 0 N/A
Lucira Health Competitors 341 626 1235 19 2.42

As a group, "Diagnostic substances" companies have a potential upside of 37.76%. Given Lucira Health's rivals higher possible upside, analysts clearly believe Lucira Health has less favorable growth aspects than its rivals.


Lucira Health beats its rivals on 7 of the 10 factors compared.

About Lucira Health

(Get Rating)

Lucira Health Inc. is a medical technology company. It is focused on the development and commercialization of transformative and infectious disease test kits. Lucira Health Inc. is based in Emeryville, California.

Receive News & Ratings for Lucira Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lucira Health and related companies with's FREE daily email newsletter.

The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment